LDR announces landmark publication in JAMA Surgery on Cost-Effectiveness of 2-Level Mobi-C(R) Cervical Disc

The paper, Ament JD, et al: Cost-Effectiveness of Cervical Total Disc Replacement vs Fusion for the Treatment of 2-Level Symptomatic Degenerative Disc Disease, JAMA Surg. was published online on October 8, 2014, with print publication to follow. The study, authored by Jared Ament, M.D., MPH with the UC Davis Health System Neurosurgery Department, utilized the clinical data from the two-level Mobi-C vs. ACDF randomized controlled trial in order to assign health states for the patient population. Costs were derived from institutional billing data at the Investigational Device Exemption (IDE) trial sites.

The research team used decision analytical modelling to generate Quality-Adjusted Life-Years (QALY) and Incremental Cost-Effectiveness Ratios (ICER) for both treatment groups. QALY is a measure of disease burden and assesses the value for the money associated with a medical intervention. QALY is based on the number of years of life that a given intervention would add to one’s life. ICER is the ratio of the change in costs to incremental benefits of a therapeutic intervention or treatment. An intervention with a lower cost to QALY saved ratio (ICER) would be preferred over an intervention with a higher ratio.

The objective of this paper was to determine the cost-effectiveness of cervical total disc replacement (CTDR) compared to ACDF for two-level cervical disc disease. The study found CTDR with Mobi-C appears to be a highly cost-effective surgical modality compared with ACDF for the treatment of two-level cervical disc disease.

Key findings of the study include:
The ICER of CTDR over ACDF is $24,594 per QALY, lower than the commonly used US ICER threshold of $50,000 per QALY, suggesting that CTDR is a “highly cost-effective option.” CTDR is not only a cost-effective option for 2-level cervical disc disease, but from a societal perspective, it imparts a greater quality of life at less cost over a 4-year period.

Christophe Lavigne, President and CEO of LDR, said

“The statistical superiority of Mobi-C compared to ACDF for two-level indications has been demonstrated through the IDE for the overall composite primary effectiveness endpoint at 24 months, and the PMA for two-level indications was approved by the FDA in 2013. In today’s US healthcare environment we knew it would be important to determine the cost-effectiveness of Mobi-C as compared to ACDF, the historical standard of care. We are excited to have this very important economic analysis of Mobi-C published, especially in such a prestigious journal as JAMA Surgery. The principal finding of this study, that Mobi-C appears to offer improved cost-effectiveness for two-level replacement (based on the 24 month outcomes), is an important factor for consideration by healthcare providers.”

Read more about the Mobi C offering here.